Southeast Asia Olmesartan Market was valued at US$ 322.8 million in 2022 and is projected to surpass a valuation of US$ 491.79 million by 2031 at a CAGRof 4.3% during the forecast period 2023–2031.

A federal judge in Camden, New Jersey, dismissed a suit accusing lawyers from Mazie, Slater, Katz & Freeman of collecting ...

2006;26(1):29-34. Conclusion: These results show that there is little or no potential for a clinically relevant pharmacokinetic interaction between olmesartan medoxomil 20mg and ...

Of these, 627 patients who showed a suboptimal response after 8 weeks of treatment with olmesartan medoxomil 20 mg/day were randomised to receive olmesartan medoxomil 40 mg/day (n = 302 ...

Olmesartan is an angiotensin II receptor blocker licensed for the treatment of hypertension. It can cause a sprue-like enteropathy (SLE), characterised by chronic diarrhoea, weight loss and villous ...

Olmesartan is an angiotensin II receptor blocker licensed for the treatment of hypertension. It can cause a sprue-like enteropathy (SLE), characterised by chronic diarrhoea, weight loss and villous ...